An Open-Label, Multi Center, Clinical Trial: External Continuous Subcutaneous Infusion of Insulin Using Insulin Aspart (NovoLog®) in Subjects With Type 1 and Insulin Requiring Type 2 Diabetes.
Phase of Trial: Phase IV
Latest Information Update: 07 Jan 2017
At a glance
- Drugs Insulin aspart (Primary) ; Insulin lispro
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 24 May 2012 Additional location (USA) added as reported by ClinicalTrials.gov.
- 27 May 2009 New trial record